Видео ютуба по тегу Trial: Monarche

MonarchE Trial
MonarchE Trial
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC
CDK4/6 for HR+ early breast cancer: monarchE results
CDK4/6 for HR+ early breast cancer: monarchE results
ESMO24 Spotlight: Patient-level analysis of the monarchE and NATALEE trial
ESMO24 Spotlight: Patient-level analysis of the monarchE and NATALEE trial
MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC
MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC
Analysis of BRCA1/2 mutations and other alterations in the monarchE trial
Analysis of BRCA1/2 mutations and other alterations in the monarchE trial
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer
MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancer
MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancer
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer
Final overall survival analysis of MONARCH 1
Final overall survival analysis of MONARCH 1
monarchE: patient-reported outcomes
monarchE: patient-reported outcomes
HR+ Breast Cancer: Updated Results From MONARCH Trials
HR+ Breast Cancer: Updated Results From MONARCH Trials
Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer
Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer
Dr. Goetz Discusses a Secondary Analysis of the MONARCH Trials in Breast Cancer
Dr. Goetz Discusses a Secondary Analysis of the MONARCH Trials in Breast Cancer
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
MONARCH-2 Trial
MONARCH-2 Trial
monarchE: adjuvant abemaciclib in HR+ breast cancer
monarchE: adjuvant abemaciclib in HR+ breast cancer
MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancer
MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancer
Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020
Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020